Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30048974 | 1.00 | KDM4E (0.58) | KDM4EMAPTALDH1A1HPGDGAA | |
| SCHEMBL25351231 | 0.87 | HDAC1 (0.55) | KDM4EMAPTALDH1A1HPGDGAA | |
| SCHEMBL4341372 | 0.85 | ALOX15 (0.63) | KDM4EMAPTALDH1A1HPGDGAA | |
| SCHEMBL31473433 | 0.83 | GAA (0.61) | KDM4EMAPTALDH1A1HPGDGAA | |
| SCHEMBL4229654 | 0.83 | GAA (0.61) | KDM4EMAPTALDH1A1HPGDGAA | |
| SCHEMBL15618544 | 0.83 | ERAP2 (0.56) | KDM4EMAPTALDH1A1HPGDGAA | |
| SCHEMBL21925191 | 0.83 | LNPEP (0.53) | KDM4EMAPTALDH1A1HPGDGAA | |
| SCHEMBL10088429 | 0.82 | SMN1; SMN2 (0.49) | KDM4EMAPTALDH1A1HPGDGAA | |
| SCHEMBL5924534 | 0.81 | MAPT (0.64) | KDM4EMAPTALDH1A1HPGDGAA | |
| SCHEMBL542066 | 0.81 | PRKCI (0.69) | KDM4EMAPTALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2024-09-17 | — | — | US | disclosed |
| CN-117561058-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2022272106-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2022-06-02 | — | — | US | disclosed |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-01-12 | — | — | US | disclosed |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190194181-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10287284-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180291015-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2018-10-11 | — | — | US | disclosed |
| US-10030011-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2536285-B1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-8759535-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2536285-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | High Point Pharmaceuticals, LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103018-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | KDM4E 2451/4885MAPT 2385/4885ALDH1A1 1872/4885 |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | KDM4E 2451/4885MAPT 2385/4885ALDH1A1 1872/4885 |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | KDM4E 2451/4885MAPT 2385/4885ALDH1A1 1872/4885 |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | KDM4E 2243/4885MAPT 1693/4885ALDH1A1 1757/4885 |
| US-10287284-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, PTGS2 | KDM4E 2243/4885MAPT 1693/4885ALDH1A1 1757/4885 |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | KDM4E 2332/4885MAPT 2557/4885ALDH1A1 1697/4885 |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | KDM4E 2451/4885MAPT 2385/4885ALDH1A1 1872/4885 |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | KDM4E 2512/4885MAPT 3481/4885ALDH1A1 3716/4885 |
| US-20190194181-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, UACA | KDM4E 2862/4885MAPT 1261/4885ALDH1A1 1046/4885 |
| US-10030011-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, PTGS2 | KDM4E 2243/4885MAPT 1693/4885ALDH1A1 1757/4885 |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GOT2, GLS2, PYGL | KDM4E 1595/4885MAPT 2411/4885ALDH1A1 491/4885 |
| US-20180291015-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | KDM4E 2243/4885MAPT 1693/4885ALDH1A1 1757/4885 |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, UACA | KDM4E 2862/4885MAPT 1261/4885ALDH1A1 1046/4885 |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | KDM4E 2451/4885MAPT 2385/4885ALDH1A1 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.